ALX Oncology (ALXO)
Nasdaq Market Open
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company developing cancer immunotherapies that are designed to help the immune system identify and attack tumour cells. Its research is centred on the CD47 pathway, a mechanism some cancers use to send a “do not eat me” signal to macrophages and other immune cells. By blocking that signal, the company aims to make malignant cells more vulnerable to immune clearance while improving on the tolerability challenges seen with earlier CD47-targeting approaches.
The company’s lead candidate is evorpacept, also known as ALX148, a next-generation CD47 blocker engineered with an inactive Fc region. This design is intended to bind CD47 with high affinity while limiting unwanted destruction of healthy blood cells, a key concern in the class. ALX Oncology evaluates evorpacept in combination with other anti-cancer treatments, including tumour-targeting antibodies, immune checkpoint inhibitors and chemotherapy, because CD47 blockade is generally viewed as a way to enhance existing therapeutic strategies rather than replace them.
As a development-stage company, ALX Oncology does not have a marketed oncology product and its valuation is closely tied to clinical trial progress, safety data, partnership potential and regulatory outcomes. Its pipeline targets both solid tumours and blood cancers, reflecting the broad role CD47 may play in immune evasion. For investors, ALXO represents exposure to a specialised area of immuno-oncology where scientific differentiation, trial execution and competitive positioning against other macrophage-checkpoint programmes are central to the investment case.
Last updated
- Market Cap
- 209.92M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 186.15M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
EnerVenue Names Steffen Pietzke as Chief Financial Officer - GlobeNewswire
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Replimune (REPL) Gains on Positive Data From Melanoma Study
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 209.92M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 186.15M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.39
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.13
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -0.66
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -78.33M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -58.72%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -49.83%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.06
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 7.21
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 7.21
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.6
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.01M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1.56
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -18.97M | -23.02M | -22.53M | -26.65M | -31.82M |
| EBITDA | -18.82M | -22.87M | -22.38M | -23.28M | -31.61M |
| Net income | -17.93M | -22.85M | -22.14M | -25.95M | -30.75M |
| Basic EPS | -0.17 | -0.42 | -0.41 | -0.49 | -0.58 |
| Diluted EPS | -0.17 | -0.42 | -0.41 | -0.49 | -0.58 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 178.33M | 59.05M | 82.72M | 95.32M | 120.9M |
| Total liabilities | 26.98M | 33.07M | 37.92M | 30.91M | 32.61M |
| Total equity | 151.35M | 25.98M | 44.8M | 64.42M | 88.3M |
| Cash & equivalents | 32.28M | 16.37M | 23.44M | 19.3M | 20.61M |
| Current assets | 145.56M | 50.73M | 66.52M | 85.26M | 102.53M |
| Current liabilities | 20.18M | 24.55M | 27.72M | 18.85M | 18.74M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -18.65M | -18.98M | -17.09M | -23.41M | -24.66M |
| Investing cash flow | -105.04M | 11.23M | 21.39M | 22.32M | 27.65M |
| Financing cash flow | 139.6M | 678K | -159K | -222K | 65K |
| Change in cash | 15.91M | -7.07M | 4.14M | -1.31M | 3.05M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13D/A — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | SCHEDULE 13G/A — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | SCHEDULE 13G/A — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 8-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 10-Q — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | DEF 14A — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | ARS — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 3 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 4 | Form 4 — Klencke Barbara | View Filing | |
| form 4 | Form 4 — Knight Jeff E. | View Filing | |
| edgar index | 8-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 4 | Form 4 — Pinto Shelly | View Filing | |
| form 4 | Form 4 — Lettmann Jason | View Filing | |
| edgar index | 10-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 3 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 3 | Form 3 — Klencke Barbara | View Filing | |
| form 3 | Form 3 — Klencke Barbara | View Filing | |
| form 3 | Form 3 — Klencke Barbara | View Filing | |
| form 3 | Form 3 — Klencke Barbara | View Filing | |
| form 3 | Form 3 — Klencke Barbara | View Filing | |
| form 4 | Form 4 — Klencke Barbara | View Filing | |
| edgar index | 8-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 4 | Form 4 — Pinto Shelly | View Filing | |
| form 4 | Form 4 — Lettmann Jason | View Filing | |
| edgar index | SCHEDULE 13G — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | SCHEDULE 13G — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | SCHEDULE 13D/A — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 4 | Form 4 — GOODMAN COREY S | View Filing | |
| form 4 | Form 4 — GOODMAN COREY S | View Filing | |
| form 4 | Form 4 — GOODMAN COREY S | View Filing | |
| form 4 | Form 4 — GOODMAN COREY S | View Filing | |
| form 4 | Form 4 — GOODMAN COREY S | View Filing | |
| edgar index | 8-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 8-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 424B5 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 4 | Form 4 — Lettmann Jason | View Filing | |
| form 4 | Form 4 — Pinto Shelly | View Filing | |
| form 4 | Form 4 — Shantharam Harish | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | 8-K — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| edgar index | S-8 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Hemrajani Rekha | View Filing | |
| form 4 | Form 4 — Takimoto Chris H | View Filing | |
| form 4 | Form 4 — Curran Daniel J. | View Filing | |
| form 4 | Form 4 — Sandler Alan B. | View Filing | |
| form 4 | Form 4 — Garland J. Scott | View Filing | |
| form 4 | Form 4 — GOODMAN COREY S | View Filing | |
| edgar index | 4 — ALX ONCOLOGY HOLDINGS INC | View Filing | |
| form 4 | Form 4 — Pinto Shelly | View Filing |